#Taiwan #Taipei #Imaging Technology #MolecuLight #DSWI

Transformative Results of MolecuLight Imaging in Taiwan

In a groundbreaking clinical study conducted at Shuang-Ho Hospital in Taipei, Taiwan, MolecuLight Inc., a leader in point-of-care fluorescence imaging, has demonstrated significant improvements in treating deep sternal wound infections (DSWI) through its innovative imaging technology, specifically the MolecuLight iX®. The study highlights how this advanced imaging solution not only enhances clinical outcomes but also substantially reduces healthcare costs associated with these complex infections.

Study Overview

Published in the Journal of Wound Care in June 2025, the study entitled Effects of Adjuvant Hyperbaric Oxygen Therapy and Real-Time Fluorescent Imaging on Deep Sternal Wound Infection: A Retrospective Study showcased remarkable findings. Utilizing MolecuLight’s imaging within existing treatment protocols led to quicker infection resolution, significantly lower antibiotic usage, and shorter hospital stays compared to traditional hyperbaric oxygen therapy (HBOT).

Key Findings

1. Enhanced Infection Control: Patients utilizing MolecuLight showed a remarkable 26-fold increase in normal white blood cell counts within seven days and an impressive seven-fold improvement in C-reactive protein normalization over 14 days compared to those receiving HBOT.
2. Reduced Antibiotic Use and Costs: The group treated with MolecuLight required antibiotics for a shorter duration—22 days versus 29.5 days—with associated costs plummeting to just $573.57 compared to $1,643.78 in the HBOT group.
3. Faster Healing Times: Patients treated with the MolecuLight system experienced a 70% reduction in intensive care unit stays, averaging only three days compared to ten days. Additionally, wound healing progressed 20% faster (40 days vs. 50 days).
4. Lower Complication Risks: The MolecuLight approach resulted in an 82% lower rate of hospital-acquired wound reinfections and an 86% reduction in recurrent osteomyelitis—a crucial factor in ensuring long-term patient health and curtailing healthcare costs.
5. Improved Debridement Effectiveness: The study underscored MolecuLight’s unique ability to enhance debridement precision, a cornerstone for effective wound management and infection control.

Expert Insights

Dr. Shun-Cheng Chang, one of the study's authors from Shuang-Ho Hospital, stated that this technology provides tangible benefits in clinical wound treatment. The ability to visualize bacteria in real time assists in training younger physicians on critical infection control and intraoperative assessment principles.

Wei-Pin Hsieh, CEO of Healtdeva Company Ltd., echoed these sentiments by emphasizing the technology's role in transforming clinical practices in Taiwan. The precise diagnostic capabilities of MolecuLight pave the way for improved patient outcomes, facilitating a deeper understanding of complex wound treatment protocols.

Anil Amlani, CEO of MolecuLight, expressed pride in the study's findings, reinforcing the clinical and economic value of the MolecuLight technology not only in wound care but also in critical surgical applications.

Conclusion

The results from this Taiwanese study are a testament to the potential of MolecuLight's imaging technology in revolutionizing the management of deep sternal wound infections. As healthcare providers continue to seek innovative solutions to enhance patient care and reduce costs, MolecuLight stands out as a game-changer in the fight against complex wound infections.

With the rising acknowledgment of the technology's advantages, its application is expected to broaden into surgical settings, benefiting doctors and patients alike. The collaboration with Healtdeva Company marks a significant step toward enhancing healthcare quality in Taiwan through advanced medical technologies.